Toshiba to develop boron neutron capture therapy (BNCT) system
Ubicación actual:
> This Story

Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment




Rad Oncology Homepage

MD Anderson to expand proton therapy center with $159 million project Increases accessibility to higher number of patients

Radiotherapy beats anti-hormonal therapy for some breast cancer patients, says study Avoiding side effects such as hot flashes, weight gain and bone fracture

New technique may concentrate radiotherapy dose for minimal tissue damage Utilizes very high energy electrons (VHEEs)

MedAustron delivers first bout of carbon ion therapy on patient Sixth center in the world to offer treatment

Research shows how hurricanes hinder radiotherapy outcomes Treatment transfers and eliminating out-of-network insurance charges could help

Elekta to distribute C-RAD SIGRT technology in North America and Mexico Advances stereotactic radiosurgery and stereotactic body radiotherapy

CMS proposes alternative payment model for radiation oncology Uses prospective, episode-based payments; ensures value-based care

FDA gives RaySearch green light for RayStation 8B platform First treatment planning system to offer machine learning applications

MedAustron to add health IT to proton and carbon ion treatment facilities Orders more than $13 million worth of RaySearch systems

'Nudge' in EHRs cuts imaging in half for palliative radiotherapy, says study Reduces duration of radiotherapy sessions

Toshiba to develop boron neutron capture therapy (BNCT) system

por Thomas Dworetzky , Contributing Reporter
Toshiba has made a new move in radiation therapy.

Just-announced plans call for it to develop a boron neutron capture therapy (BNCT) machine and to focus on melanoma treatment trials as early as fiscal 2017.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

It will take the place of Mitsubishi Heavy Industries in the KEK project led by the University of Tsukuba and the High Energy Accelerator Research Organization, according to the Nikkei Asian Review.

The company had kept its heavy particle radiation systems after selling Toshiba Medical Systems to Canon.

That sale was not without significant controversy, however, as HCB News reported in July.

After the sale, regulators “decided to make an announcement about the warning to let everyone know that it is not acceptable, so the same method won’t be used in the future,” Takeshi Shinagawa, director of the Fair Trade Commission's (FTC) mergers-and-acquisitions division, told a news conference.

Toshiba avoided potential regulatory issues by selling Canon "MS Holding", a "special-purpose vehicle with $300 in capital that was created just to conduct the transaction." This stripped voting control from its medical unit and gave it to the vehicle. MS Holding had just three shareholders — the former head of trading house Sumitomo Corporation, a lawyer, and an accountant — each owning one-third of the entity.

Complaints over the highly unusual maneuver came from other Toshiba suitors, notably losing bidder Fujifilm Holdings, which expressed outrage over the trick, noting that it "would make a mockery of the law," according to a report at the time by HCB News.

The key to the BNCT breakthrough was development of a novel boron carrier – a specially devised tiny capsule – that binds to albumin, which in turn let boron be carried preferentially to tumor cells. The capsule, constructed out of maleimide-functionalized closo-dodecaborate (MID), was created by researchers at the Tokyo Institute of Technology led by Hiroyuki Nakamura, according to a release by that institution on a paper just published in the Journal of Controlled Release.

The non-damaging neutron beam “excites the boron to release high-energy charged particles that can kill the cancer cells,” according to Nikkei Asian Review.

This occurs because albumin collects malignant tissues. “In fact, it is a major source of nutrition for growing tumors,” according to Science Daily.
  Pages: 1 - 2 >>

Rad Oncology Homepage

You Must Be Logged In To Post A Comment